Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial

The American Journal of Psychiatry
Rajesh GopalakrishnanJacob K John

Abstract

Antipsychotic-induced erectile dysfunction is a significant clinical problem and is a common reason for poor medication compliance. This report studied the efficacy and tolerability of sildenafil citrate in patients with antipsychotic-induced erectile dysfunction. The study design was a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial carried out at a tertiary referral center. Thirty-two married male outpatients with schizophrenia or delusional disorder and antipsychotic-induced erectile dysfunction were recruited for the trial. Sexual function was assessed from patient logs of sexual activity. Thirty-two subjects and their spouses, who agreed to take part in the study, were included in the crossover trial. Thirty-one (96.9%) completed the trial. There was no significant period effect or treatment-period interaction. Patients reported significant improvement while taking sildenafil in the number of adequate erections, satisfaction with sexual intercourse, and the duration of erections over 2 weeks. The odds ratios for adequate erections and for satisfactory sexual intercourse with sildenafil were 4.07 and 3.77, respectively. The effect of sildenafil remained significant even after adjustment ...Continue Reading

Citations

Aug 22, 2008·Psychopharmacology·Donald C GoffJared P Walsh
Dec 22, 2006·International Journal of Impotence Research·S Doggrell
Dec 18, 2007·Sexual Health·David PlevinPenny Roughan
Feb 7, 2007·Current Opinion in Psychiatry·Peter Malik
Dec 1, 2007·Clinical Interventions in Aging·Konstantinos Hatzimouratidis
Oct 15, 2009·International Journal of Environmental Research and Public Health·Alexander M PonizovskyAlexander Grinshpoon
Jan 1, 2008·Primary Care Companion to the Journal of Clinical Psychiatry·Blanka Kores Plesnicar, Andrej Plesnicar
Jan 1, 2010·Indian Journal of Psychiatry·T S Sathyanarayana RaoK S J Rao
Nov 13, 2010·Indian Journal of Nephrology·A GhafariS Hatami
Dec 3, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Akira FujiiSunao Kaneko
Mar 3, 2009·L'Encéphale·A CharpentierP Thomas
Mar 15, 2008·Human Psychopharmacology·Martin Baggaley
Dec 17, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tsutomu KikuchiNorio Ozaki
Feb 28, 2015·Schizophrenia Bulletin·Marrit K de BoerHenderikus Knegtering
Apr 19, 2013·The World Journal of Men's Health·Yeon Won ParkJun Ho Lee
Aug 16, 2016·The Psychiatric Clinics of North America·Anita H ClaytonJennifer G Votta
Feb 6, 2015·The Cochrane Database of Systematic Reviews·Nicola MaayanClive E Adams
Nov 16, 2012·The Cochrane Database of Systematic Reviews·Hannah M SchmidtMichael M Berner
Jul 28, 2006·CNS Spectrums·Glen L Stimmel, Mary A Gutierrez
Nov 6, 2017·Postgraduate Medical Journal·Shirin RazdanRanjith Ramasamy
Sep 16, 2020·Health Technology Assessment : HTA·Michael J CrawfordThomas Re Barnes
Jan 21, 2021·Journal of Clinical Medicine·Angel L MontejoLaura Montejo

❮ Previous
Next ❯

Software Mentioned

SAS
SPSS

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here